Literature DB >> 26130567

Optimization of experimental conditions for functional in vitro characterization of humanized antibodies specific for staphylococcal enterotoxin B.

Jennifer L MacIntyre1, Avanish K Varshney2, Xiaobo Wang2, Scott Gatto3, Clarence Friedman3, Yan Liu3, Kelvin Kerns3, Oleg Kovalenko3, Karissa Adkins4, Richard Zollner3, Bettina C Fries5, Fergus R Byrne6.   

Abstract

Staphylococcus aureus is a common nosocomial infection and its resistance to penicillin and methicillin antibiotics is a growing clinical problem. We previously described the development of a humanized anti-Staphylococcus enterotoxin B (SEB) antibody derived from the mouse antibody made by the 20B1 hybridoma. This antibody was humanized and characterized kinetically by surface plasmon resonance demonstrating that the humanized clones retained binding to SEB. Clones were then functionally characterized in an in vitro assay demonstrating that the murine 20B1, chimeric and humanized antibodies potently inhibited SEB-induced murine splenocyte proliferation assay. Here, we describe a human cell-based screening assay, optimized by varying multiple experimental parameters that resulted in an assay that was used to demonstrate full and potent neutralization by the parental, chimeric and humanized antibodies. The replacement of fetal bovine serum (FBS) with normal human serum (NHS) was found to be a crucial factor in the performance of the human cell based screening assay that enabled the calculation of mAb efficacy and potency. In addition, we found that anti-SEB antibodies showed similar efficacy and potency with a triple mutant Fc region (designed to be effector function null) or a wild-type Fc region, which is in contrast to previously described studies.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Humanized antibodies; In vitro; SEB; Staphylococcus aureus

Mesh:

Substances:

Year:  2015        PMID: 26130567      PMCID: PMC5793905          DOI: 10.1016/j.intimp.2015.06.025

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  9 in total

Review 1.  Vaccines against the category B toxins: Staphylococcal enterotoxin B, epsilon toxin and ricin.

Authors:  Nicholas J Mantis
Journal:  Adv Drug Deliv Rev       Date:  2005-06-17       Impact factor: 15.470

2.  Identification of the Fc gamma receptor class I binding site in human IgG through the use of recombinant IgG1/IgG2 hybrid and point-mutated antibodies.

Authors:  M S Chappel; D E Isenman; M Everett; Y Y Xu; K J Dorrington; M H Klein
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-15       Impact factor: 11.205

3.  Severe atopic dermatitis is associated with sensitization to staphylococcal enterotoxin B (SEB).

Authors:  K Breuer; M Wittmann; B Bösche; A Kapp; T Werfel
Journal:  Allergy       Date:  2000-06       Impact factor: 13.146

Review 4.  Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies.

Authors:  Frank R Brennan; Laura Dill Morton; Sebastian Spindeldreher; Andrea Kiessling; Roy Allenspach; Adam Hey; Patrick Y Muller; Werner Frings; Jennifer Sims
Journal:  MAbs       Date:  2010-05-23       Impact factor: 5.857

5.  Potent neutralization of staphylococcal enterotoxin B by synergistic action of chimeric antibodies.

Authors:  Mulualem E Tilahun; Govindarajan Rajagopalan; Nalini Shah-Mahoney; Rebecca G Lawlor; Ashenafi Y Tilahun; Chen Xie; Kannan Natarajan; David H Margulies; David I Ratner; Barbara A Osborne; Richard A Goldsby
Journal:  Infect Immun       Date:  2010-03-22       Impact factor: 3.441

6.  Humanized staphylococcal enterotoxin B (SEB)-specific monoclonal antibodies protect from SEB intoxication and Staphylococcus aureus infections alone or as adjunctive therapy with vancomycin.

Authors:  Avanish K Varshney; Xiaobo Wang; Jennifer MacIntyre; Richard S Zollner; Kerry Kelleher; Oleg V Kovalenko; Ximo Pechuan; Fergus R Byrne; Bettina C Fries
Journal:  J Infect Dis       Date:  2014-05-05       Impact factor: 5.226

7.  Inhibition of toxic shock by human monoclonal antibodies against staphylococcal enterotoxin B.

Authors:  Eileen A Larkin; Bradley G Stiles; Robert G Ulrich
Journal:  PLoS One       Date:  2010-10-11       Impact factor: 3.240

8.  Staphylococcal Enterotoxin B-specific monoclonal antibody 20B1 successfully treats diverse Staphylococcus aureus infections.

Authors:  Avanish K Varshney; Xiaobo Wang; Matthew D Scharff; Jennifer MacIntyre; Richard S Zollner; Oleg V Kovalenko; Luis R Martinez; Fergus R Byrne; Bettina C Fries
Journal:  J Infect Dis       Date:  2013-08-06       Impact factor: 5.226

9.  Generation and characterization of high affinity human monoclonal antibodies that neutralize staphylococcal enterotoxin B.

Authors:  Brian Drozdowski; Yuhong Zhou; Brad Kline; Jared Spidel; Yin Yin Chan; Earl Albone; Howard Turchin; Qimin Chao; Marianne Henry; Jacqueline Balogach; Eric Routhier; Sina Bavari; Nicholas C Nicolaides; Philip M Sass; Luigi Grasso
Journal:  J Immune Based Ther Vaccines       Date:  2010-12-21
  9 in total
  3 in total

1.  Effective Treatment of Staphylococcal Enterotoxin B Aerosol Intoxication in Rhesus Macaques by Using Two Parenterally Administered High-Affinity Monoclonal Antibodies.

Authors:  Daniel Verreault; Jane Ennis; Kevin Whaley; Stephanie Z Killeen; Hatice Karauzum; M Javad Aman; Rick Holtsberg; Lara Doyle-Meyers; Peter J Didier; Larry Zeitlin; Chad J Roy
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

2.  Computational Construction of a Single-Chain Bi-Paratopic Antibody Allosterically Inhibiting TCR-Staphylococcal Enterotoxin B Binding.

Authors:  Ganggang Bai; Yanhong Ge; Yuhong Su; Shuo Chen; Xingcheng Zeng; Huixia Lu; Buyong Ma
Journal:  Front Immunol       Date:  2021-11-23       Impact factor: 7.561

3.  Contribution of Staphylococcal Enterotoxin B to Staphylococcus aureus Systemic Infection.

Authors:  Justin S Bae; Fei Da; Ryan Liu; Lei He; Huiying Lv; Emilie L Fisher; Govindarajan Rajagopalan; Min Li; Gordon Y C Cheung; Michael Otto
Journal:  J Infect Dis       Date:  2021-05-28       Impact factor: 5.226

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.